Charles River Laboratories International, Inc.’s stock price dips to $123.61, marking a 7.80% decrease: Unpacking the performance

Charles River Laboratories International, Inc. (CRL)

123.61 USD -10.46 (-7.80%) Volume: 1.59M

Charles River Laboratories International, Inc.’s stock price stands at 123.61 USD, marking a 7.80% decrease in this trading session with a trading volume of 1.59M. The stock has experienced a significant YTD decline of 33.04%, suggesting a challenging market performance for CRL.

Latest developments on Charles River Laboratories International, Inc.

Today, Charles River Laboratories International Inc. stock underperformed compared to its competitors, with Goldman Sachs adjusting the company’s price target to $150 from $170 while maintaining a neutral rating. This news comes as Charles River Labs stock hit a 52-week low at $132.57, according to Investing.com. These events have contributed to the fluctuations in Charles River Laboratories‘ stock price movements today.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. provides research tools and support services for drug discovery and development. With a mixed outlook based on Smartkarma Smart Scores, the company scores well in value and momentum, indicating a positive long-term outlook. However, its scores in dividend, growth, and resilience are lower, suggesting potential challenges in those areas. Overall, Charles River Laboratories serves a variety of customers in the pharmaceutical and biotechnology industries, as well as hospitals and academic institutions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma